We conducted a phase 2 trial to evaluate the safety and efficacy of bendamustine instead of
BCNU (carmustine) in the BEAM (BCNU, etoposide, cytarabine and melphalan) regimen …

Background Bendamustine is an attractive option for the management of both de novo and
relapsed lymphomas. It is being increasingly used in the conditioning regimen for …

Carmustine shortage has led to an increase use of alternative conditioning regimens prior to
autologous stem cell transplantation for the treatment of lymphoma, including Bendamustine …

BEAM conditioning regimen (carmustine [BCNU], etoposide, cytarabine, and melphalan)
has been widely used for autologous stem cell transplantation in patients with relapsed or …

We designed a phase 1-2 study to evaluate the safety and the efficacy of increasing doses of
bendamustine (160 mg/m2, 180 mg/m2, and 200 mg/m2 given on days− 7 and− 6) coupled …

With the advent of new cellular and targeted therapies, treatment options for relapsed and
refractory (r/R) lymphomas have multiplied, and the optimal approach offering the best …

Background Replacement of carmustine (BCNU) in the BEAM regimen (BCNU, etoposide,
cytarabine, melphalan) with bendamustine (BendaEAM) before autologous stem cell …

Bendamustine has shown a favorable safety profile when included in chemotherapy
regimens for several types of lymphoma, including CLL. This study investigated the long …

Unavailability of Carmustine and its dramatically increased cost by nearly 10 fold has led to
its replacement by bendamustine (Be) and an increase use of Bendamustine-based …

High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a
standard of care for patients with relapsed aggressive non-HodgkinLs lymphoma (NHL). 1, 2 …